If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email email@example.com.
Please tell us what format you need. It will help us if you say what assistive technology you use.
In November 2018 revised guidance for healthcare professionals on the use of immunoglobulins for the treatment of clinical tetanus and the management of tetanus prone wounds was issued.
Tetanus is an acute disease caused by the action of tetanus toxin, released following infection by the bacterium Clostridium tetani.